Pfizer's (PFE) Inlyta treamtent for advanced kidney cancer "narrowly missed" its primary...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Pfizer's (PFE) Inlyta treamtent for advanced kidney cancer "narrowly missed" its primary endpoint in a Phase III trial of patients who had not yet been treated for the illness. While the drug, also called axitinib, had a median progression-free survival better than that of rival treatment sorafenib, the results weren't statistically significant. Pfizer is now evaluating whether further studies are worthwhile. (PR)